ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
124.850,18
0,38%
S&P 500
6.115,07
1,04%
US Dollar vs BRL
5,7684
0,00%
Bitcoin
96.702,70
0,09%
Brent Oil
75,025
-0,09%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. ZyVersa Therapeutics Inc (ZVSA)

  7. ZyVersa Therapeutics Inc (ZVSA) Notícias

ZVSA

ZyVersa Therapeutics (ZVSA)

ZyVersa Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ZVSA
DataHoraFonteTítuloCódigoCompanhia
24/01/202518:05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ZVSAZyVersa Therapeutics Inc
17/01/202518:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ZVSAZyVersa Therapeutics Inc
30/12/202410:30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ZVSAZyVersa Therapeutics Inc
27/12/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ZVSAZyVersa Therapeutics Inc
20/12/202419:04Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ZVSAZyVersa Therapeutics Inc
20/12/202418:15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ZVSAZyVersa Therapeutics Inc
18/12/202409:55GlobeNewswire Inc.ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San FranciscoNASDAQ:ZVSAZyVersa Therapeutics Inc
20/11/202409:55GlobeNewswire Inc.ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical TrialNASDAQ:ZVSAZyVersa Therapeutics Inc
15/11/202410:35GlobeNewswire Inc.Life Sciences Investor Forum: Presentations Now Available for Online ViewingNASDAQ:ZVSAZyVersa Therapeutics Inc
14/11/202410:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVSAZyVersa Therapeutics Inc
14/11/202410:10GlobeNewswire Inc.ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business UpdateNASDAQ:ZVSAZyVersa Therapeutics Inc
14/11/202410:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZVSAZyVersa Therapeutics Inc
05/11/202409:00GlobeNewswire Inc.ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 DiabetesNASDAQ:ZVSAZyVersa Therapeutics Inc
29/10/202408:57GlobeNewswire Inc.ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss DrugsNASDAQ:ZVSAZyVersa Therapeutics Inc
22/10/202408:57GlobeNewswire Inc.ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative DiseasesNASDAQ:ZVSAZyVersa Therapeutics Inc
17/10/202408:50GlobeNewswire Inc.ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine MonthsNASDAQ:ZVSAZyVersa Therapeutics Inc
15/10/202408:50GlobeNewswire Inc.ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome InhibitorsNASDAQ:ZVSAZyVersa Therapeutics Inc
07/10/202408:55GlobeNewswire Inc.ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic ComplicationsNASDAQ:ZVSAZyVersa Therapeutics Inc
16/09/202418:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ZVSAZyVersa Therapeutics Inc
09/09/202417:35Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ZVSAZyVersa Therapeutics Inc
09/09/202417:32Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ZVSAZyVersa Therapeutics Inc
09/08/202417:40GlobeNewswire Inc.ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business UpdateNASDAQ:ZVSAZyVersa Therapeutics Inc
07/08/202408:50GlobeNewswire Inc.ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic InflammationNASDAQ:ZVSAZyVersa Therapeutics Inc
29/07/202408:45GlobeNewswire Inc.ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older AdultsNASDAQ:ZVSAZyVersa Therapeutics Inc
25/07/202408:57GlobeNewswire Inc.ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100NASDAQ:ZVSAZyVersa Therapeutics Inc
18/07/202422:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVSAZyVersa Therapeutics Inc
18/07/202412:18GlobeNewswire Inc.ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal ModelNASDAQ:ZVSAZyVersa Therapeutics Inc
09/07/202408:57GlobeNewswire Inc.ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024NASDAQ:ZVSAZyVersa Therapeutics Inc
15/05/202409:35GlobeNewswire Inc.ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business UpdateNASDAQ:ZVSAZyVersa Therapeutics Inc
15/05/202409:25Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:ZVSAZyVersa Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ZVSA

Seu Histórico Recente

NASDAQ
CIUMX
Cibc 2025 Us Investment ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios